Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Björn Stollenwerk

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Health Policy (Amsterdam, Netherlands)|February 7, 2015
The excess health care costs of KardioPro, an integrated care program for coronary heart disease preventionChristian Becker, Rolf Holle, Björn Stollenwerk
Plos One|May 3, 2013
The association between health system development and the burden of cardiovascular disease: an analysis of WHO country profilesYanmei Liu, Koustuv Dalal, Björn Stollenwerk
Plos One|December 20, 2012
Breast cancer attributable costs in Germany: a top-down approach based on sickness funds dataEmil Victor Gruber, Stephanie Stock, Björn Stollenwerk
BMC Health Services Research|April 12, 2014
The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancerFlorian Koerber, Raphaela Waidelich, Björn Stollenwerk, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 5, 2015
Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approachBjörn Stollenwerk, Thomas Welchowski, Matthias Vogl, et al.
Journal of Medical Economics|January 5, 2026
Cost-effectiveness of sotorasib versus adagrasib in previously treated <i>KRAS</i> G12C-mutated advanced NSCLC: a US healthcare payer perspectiveNadia Karim, David Waterhouse, Simon Jones, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 18, 2013
Link between process and appraisal in coverage decisions: an analysis with structural equation modelingKatharina E Fischer, Björn Stollenwerk, Wolf H Rogowski
Pharmacoeconomics|November 19, 2014
Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillationAlexander Mensch, Stephanie Stock, Björn Stollenwerk, et al.
Journal of Medical Economics|August 15, 2017
Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapyBjörn Stollenwerk, Sergio Iannazzo, Kerry Cooper, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 1, 2013
Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluationBjörn Stollenwerk, Afschin Gandjour, Markus Lüngen, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Health Policy (Amsterdam, Netherlands)|February 7, 2015
The excess health care costs of KardioPro, an integrated care program for coronary heart disease preventionChristian Becker, Rolf Holle, Björn Stollenwerk
Plos One|May 3, 2013
The association between health system development and the burden of cardiovascular disease: an analysis of WHO country profilesYanmei Liu, Koustuv Dalal, Björn Stollenwerk
Plos One|December 20, 2012
Breast cancer attributable costs in Germany: a top-down approach based on sickness funds dataEmil Victor Gruber, Stephanie Stock, Björn Stollenwerk
BMC Health Services Research|April 12, 2014
The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancerFlorian Koerber, Raphaela Waidelich, Björn Stollenwerk, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 5, 2015
Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approachBjörn Stollenwerk, Thomas Welchowski, Matthias Vogl, et al.
Journal of Medical Economics|January 5, 2026
Cost-effectiveness of sotorasib versus adagrasib in previously treated <i>KRAS</i> G12C-mutated advanced NSCLC: a US healthcare payer perspectiveNadia Karim, David Waterhouse, Simon Jones, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 18, 2013
Link between process and appraisal in coverage decisions: an analysis with structural equation modelingKatharina E Fischer, Björn Stollenwerk, Wolf H Rogowski
Pharmacoeconomics|November 19, 2014
Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillationAlexander Mensch, Stephanie Stock, Björn Stollenwerk, et al.
Journal of Medical Economics|August 15, 2017
Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapyBjörn Stollenwerk, Sergio Iannazzo, Kerry Cooper, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 1, 2013
Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluationBjörn Stollenwerk, Afschin Gandjour, Markus Lüngen, et al.
Pageof 6